EXACT Therapeutics AS Logo

EXACT Therapeutics AS

Biopharma firm using ultrasound to enhance drug delivery for oncology via its ACT® platform.

EXTX | OL

Overview

Corporate Details

ISIN(s):
NO0010852205 (+1 more)
LEI:
2138006ZE5JAL39AGD55
Country:
Norway
Address:
Østre Aker vei 19, 0581 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing a technology platform for targeted therapeutic enhancement called Acoustic Cluster Therapy (ACT®). The company's vision is to become a leading precision medicine company by utilizing ultrasound to improve drug delivery in oncology. The proprietary ACT® platform uses a biomechanical mode of action to increase the uptake of co-administered drugs from blood vessels into the surrounding cancer tissue without damaging capillary walls. This technology is designed to be compatible with existing hospital ultrasound systems, requires no drug reformulation, and has shown potential in targeting tumors and crossing the blood-brain barrier. A key focus area is pancreatic cancer, with a clinical program in Phase 2 trials.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-25 12:57
Investor Presentation
EXACT Therapeutics to present company update - Attachment: 251125 Exact Therap…
English 1.5 MB
2025-11-25 12:57
Report Publication Announcement
EXACT Therapeutics to present company update
English 1.1 KB
2025-11-24 08:25
Director's Dealing
EXACT Therapeutics AS: New option program and receipt of share options by prima…
English 112.5 KB
2025-11-24 08:25
Remuneration Information
EXACT Therapeutics AS: New option program and receipt of share options by prima…
English 2.2 KB
2025-09-25 08:00
Interim / Quarterly Report
EXACT Therapeutics first half 2025 interim results - Attachment: EXACT Therape…
English 743.7 KB
2025-09-25 08:00
Report Publication Announcement
EXACT Therapeutics first half 2025 interim results
English 1.4 KB
2025-09-18 08:00
Regulatory Filings
EXACT Therapeutics’ Phase 2 trial to be presented at the 2025 AACR Special Conf…
English 2.0 KB
2025-09-09 08:00
Regulatory Filings
EXACT Therapeutic’s Acoustic Cluster Therapy to be presented at the Ninth Inter…
English 2.0 KB
2025-08-12 08:30
Regulatory Filings
EXACT Therapeutics to Present at the European Society for Medical Oncology (ESM…
English 1.8 KB
2025-08-11 11:08
Report Publication Announcement
Financial calendar
English 430 bytes
2025-07-08 08:30
Legal Proceedings Report
EXACT Therapeutics announces grant of core patent in the U.S.
English 1.9 KB
2025-06-24 08:00
Regulatory Filings
EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients w…
English 3.0 KB
2025-06-13 12:09
Director's Dealing
EXACT Therapeutics AS: Primary insider notification - Attachment: Notification …
English 41.4 KB
2025-06-13 12:09
Board/Management Information
EXACT Therapeutics AS: Primary insider notification
English 1.3 KB
2025-06-13 12:05
AGM Information
EXACT Therapeutics minutes from Annual General Meeting June 13, 2025 - Attachme…
Norwegian 729.7 KB

Automate Your Workflow. Get a real-time feed of all EXACT Therapeutics AS filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EXACT Therapeutics AS

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EXACT Therapeutics AS via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM

Talk to a Data Expert

Have a question? We'll get back to you promptly.